Study of REM-422 for advanced adenoid cystic carcinoma
Part of Cancer clinical trials.
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have adenoid cystic carcinoma that has spread, come back, or cannot be surgically removed.
- Your cancer must be worsening, or you must have symptoms from it.
- For the later part of the study, your tumor must have a specific genetic change called MYB positive.
- You must be able to swallow pills and have had no major stomach or bowel surgery that affects absorption.
- You must agree to use effective birth control if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether focused radiation (SBRT) can help control adenoid cystic carcinoma that has spread to a small number of places (oligometastatic disease). If you qualify, the study will treat up to 1–5 metastatic spots that doctors think can be safely targeted, to help control the cancer locally.
This Phase 1/2 study tests how well CB-103 works in people with advanced, hard-to-treat adenoid cystic carcinoma that has a specific NOTCH pathway change. The study also looks at whether combining CB-103 with either lenvatinib or abemaciclib is safe and effective for different groups of patients.
This clinical trial studies an experimental drug called AZD8205 for people with a specific type of advanced adenoid cystic carcinoma (ACC). ACC is a rare cancer that usually starts in the salivary glands. The trial aims to see if the drug can shrink tumors or slow the disease, and it's for those whose cancer has spread or come back and fits certain molecular features.
This study is testing whether focused radiation therapy (called SBRT) can control cancer that has spread to a few places in patients with a rare cancer called adenoid cystic carcinoma. It compares this treatment with watching the cancer closely without active treatment, to see which is better.
This trial tests a drug called enfortumab vedotin for people with adenoid cystic carcinoma (ACC) that has spread or come back. The drug is given through a vein and may help shrink tumors or slow the cancer.
This trial tests a new drug called HG146 for people with advanced adenoid cystic carcinoma that has progressed despite previous treatments. The goal is to see if HG146 can slow or stop the cancer from growing.
Hear when a new Adenoid Cystic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.